Related Experiment Video
Updated: Jun 30, 2026

11:54
Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
Published on: January 21, 2018
30.0K
Pembrolizumab-Induced Nasal Polyposis: The First Reported Case.
Justin M Hintze1,2, Holly Jones1,2, Peter Lacy1,2
1Department of Otolaryngology, Beaumont Hospital, Dublin, Ireland.
Journal of Rhinology : Official Journal of the Korean Rhinologic Society
|December 12, 2024
Summary
Pembrolizumab, an immune checkpoint inhibitor, can cause chronic rhinosinusitis with nasal polyposis. This case study details a patient successfully treated with surgery, highlighting a rare side effect of cancer immunotherapy.
Area of Science:
- Oncology
- Immunology
- Otolaryngology
Background:
- Immune checkpoint inhibitors (ICIs) like pembrolizumab are widely used for cancer treatment.
- Long-term side effect profiles of ICIs are not fully understood.
- Nasal polyposis is a rare but significant adverse event associated with ICI therapy.

